_id
69104fd3ccc777a4e85d53c0
Ticker
CLLS
Name
Cellectis SA
Exchange
NASDAQ
Address
8, rue de la Croix Jarry, Paris, France, 75013
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.cellectis.com
Description
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Last Close
5.22
Volume
47043
Current Price
4.68
Change
-10.344827586206899
Last Updated
2025-11-29T11:33:02.373Z
Image
data:image/webp;base64,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
Ipo Date
2007-02-07T00:00:00.000Z
Market Cap
526307968
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.23959166666666665
Sentiment Sources
12
Rating
3.8
Target Price
7.2
Strong Buy
1
Buy
2
Hold
2
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
35172000
Cost Of Revenue
2357000
Gross Profit
32815000
Operating Expenses
24774000
Operating Income
8041000
Interest Expense
2107000
Pretax Income
589000
Net Income
589000
Eps
0.0058709195115873416
Dividends Per Share
0
Shares Outstanding
72325229
Income Tax Expense
-
EBITDA
7707000
Operating Margin
22.861935630615264
Total Other Income Expense Net
-7452000
Cash
52243000
Short Term Investments
137980000
Receivables
8055999
Inventories
-
Total Current Assets
221193000
Property Plant Equipment
66709999
Total Assets
343045000
Payables
16094999
Short Term Debt
8330999
Long Term Debt
49739000
Total Liabilities
242567000
Equity
100478000
Depreciation
5011000
Change In Working Capital
1674000
Cash From Operations
-1571000
Capital Expenditures
1181000
Cash From Investing
-3441000
Cash From Financing
-4260000
Net Change In Cash
-7566000
PE
-
PB
4.672873663886621
ROE
0.586197973685782
ROA
0.17169759069509832
FCF
-2752000
Fcf Percent
-0.07824405777322871
Piotroski FScore
2
Health Score
31
Deep Value Investing Score
4.5
Defensive Investing Score
5.5
Dividend Investing Score
3.5
Economic Moat Investing Score
3.8
Garp Investing Score
3
Growth Investing Score
3
Momentum Investing Score
3
Net Net Investing Score
1
Quality Investing Score
2.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
35172000
Quarters > 0 > income Statement > cost Of Revenue
2357000
Quarters > 0 > income Statement > gross Profit
32815000
Quarters > 0 > income Statement > operating Expenses
24774000
Quarters > 0 > income Statement > operating Income
8041000
Quarters > 0 > income Statement > interest Expense
2107000
Quarters > 0 > income Statement > pretax Income
589000
Quarters > 0 > income Statement > net Income
589000
Quarters > 0 > income Statement > eps
0.0058709195115873416
Quarters > 0 > income Statement > dividends Per Share
0
Quarters > 0 > income Statement > shares Outstanding
100325000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
7707000
Quarters > 0 > income Statement > operating Margin
22.861935630615264
Quarters > 0 > income Statement > total Other Income Expense Net
-7452000
Quarters > 0 > balance Sheet > cash
52243000
Quarters > 0 > balance Sheet > short Term Investments
137980000
Quarters > 0 > balance Sheet > receivables
8055999
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
221193000
Quarters > 0 > balance Sheet > property Plant Equipment
66709999
Quarters > 0 > balance Sheet > total Assets
343045000
Quarters > 0 > balance Sheet > payables
16094999
Quarters > 0 > balance Sheet > short Term Debt
8330999
Quarters > 0 > balance Sheet > long Term Debt
49739000
Quarters > 0 > balance Sheet > total Liabilities
242567000
Quarters > 0 > balance Sheet > equity
100478000
Quarters > 0 > cash Flow > net Income
589000
Quarters > 0 > cash Flow > depreciation
5011000
Quarters > 0 > cash Flow > change In Working Capital
1674000
Quarters > 0 > cash Flow > cash From Operations
-1571000
Quarters > 0 > cash Flow > capital Expenditures
1181000
Quarters > 0 > cash Flow > cash From Investing
-3441000
Quarters > 0 > cash Flow > cash From Financing
-4260000
Quarters > 0 > cash Flow > net Change In Cash
-7566000
Quarters > 0 > ratios > PE
0.0058709195115873416
Quarters > 0 > ratios > PB
4.672873663886621
Quarters > 0 > ratios > ROE
0.586197973685782
Quarters > 0 > ratios > ROA
0.17169759069509832
Quarters > 0 > ratios > FCF
-2752000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-0.07824405777322871
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
16725000
Quarters > 1 > income Statement > cost Of Revenue
2425000
Quarters > 1 > income Statement > gross Profit
14300000
Quarters > 1 > income Statement > operating Expenses
23887000
Quarters > 1 > income Statement > operating Income
-9587000
Quarters > 1 > income Statement > interest Expense
2081908
Quarters > 1 > income Statement > pretax Income
-23736000
Quarters > 1 > income Statement > net Income
-23735000
Quarters > 1 > income Statement > eps
-0.23658111138798904
Quarters > 1 > income Statement > dividends Per Share
0
Quarters > 1 > income Statement > shares Outstanding
100325000
Quarters > 1 > income Statement > income Tax Expense
-1000
Quarters > 1 > income Statement > EBITDA
-16664000
Quarters > 1 > income Statement > operating Margin
-57.32137518684603
Quarters > 1 > income Statement > total Other Income Expense Net
-14149000
Quarters > 1 > balance Sheet > cash
59809000
Quarters > 1 > balance Sheet > short Term Investments
136341000
Quarters > 1 > balance Sheet > receivables
29370000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
230641000
Quarters > 1 > balance Sheet > property Plant Equipment
70173000
Quarters > 1 > balance Sheet > total Assets
353966000
Quarters > 1 > balance Sheet > payables
17522000
Quarters > 1 > balance Sheet > short Term Debt
12946000
Quarters > 1 > balance Sheet > long Term Debt
49563000
Quarters > 1 > balance Sheet > total Liabilities
256855000
Quarters > 1 > balance Sheet > equity
97111000
Quarters > 1 > cash Flow > net Income
-23735000
Quarters > 1 > cash Flow > depreciation
5017000
Quarters > 1 > cash Flow > change In Working Capital
-12266000
Quarters > 1 > cash Flow > cash From Operations
-10310000
Quarters > 1 > cash Flow > capital Expenditures
305000
Quarters > 1 > cash Flow > cash From Investing
-52717000
Quarters > 1 > cash Flow > cash From Financing
-4271000
Quarters > 1 > cash Flow > net Change In Cash
-67827000
Quarters > 1 > ratios > PE
-0.23658111138798904
Quarters > 1 > ratios > PB
4.834889971269989
Quarters > 1 > ratios > ROE
-24.44110347952343
Quarters > 1 > ratios > ROA
-6.705446285801461
Quarters > 1 > ratios > FCF
-10615000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.634678624813154
Quarters > 1 > health Score
16
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
10655000
Quarters > 2 > income Statement > cost Of Revenue
2015000
Quarters > 2 > income Statement > gross Profit
8640000
Quarters > 2 > income Statement > operating Expenses
22819000
Quarters > 2 > income Statement > operating Income
-14179000
Quarters > 2 > income Statement > interest Expense
1911000
Quarters > 2 > income Statement > pretax Income
-18127000
Quarters > 2 > income Statement > net Income
-18128000
Quarters > 2 > income Statement > eps
-0.18099663348058911
Quarters > 2 > income Statement > dividends Per Share
0
Quarters > 2 > income Statement > shares Outstanding
100156559
Quarters > 2 > income Statement > income Tax Expense
1000
Quarters > 2 > income Statement > EBITDA
-11285000
Quarters > 2 > income Statement > operating Margin
-133.07367433129986
Quarters > 2 > income Statement > total Other Income Expense Net
-3948000
Quarters > 2 > balance Sheet > cash
127636000
Quarters > 2 > balance Sheet > short Term Investments
114055000
Quarters > 2 > balance Sheet > receivables
25521000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
271824000
Quarters > 2 > balance Sheet > property Plant Equipment
72933000
Quarters > 2 > balance Sheet > total Assets
364086000
Quarters > 2 > balance Sheet > payables
17209000
Quarters > 2 > balance Sheet > short Term Debt
12901000
Quarters > 2 > balance Sheet > long Term Debt
45729000
Quarters > 2 > balance Sheet > total Liabilities
247882000
Quarters > 2 > balance Sheet > equity
116204000
Quarters > 2 > cash Flow > net Income
-18128000
Quarters > 2 > cash Flow > depreciation
4931000
Quarters > 2 > cash Flow > change In Working Capital
-11219000
Quarters > 2 > cash Flow > cash From Operations
-17160000
Quarters > 2 > cash Flow > capital Expenditures
395000
Quarters > 2 > cash Flow > cash From Investing
4223000
Quarters > 2 > cash Flow > cash From Financing
-4090000
Quarters > 2 > cash Flow > net Change In Cash
-15615000
Quarters > 2 > ratios > PE
-0.18099663348058911
Quarters > 2 > ratios > PB
4.033705346803896
Quarters > 2 > ratios > ROE
-15.600151457781145
Quarters > 2 > ratios > ROA
-4.979043412820048
Quarters > 2 > ratios > FCF
-17555000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-1.647583294228062
Quarters > 2 > health Score
16
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
12717000
Quarters > 3 > income Statement > cost Of Revenue
2515000
Quarters > 3 > income Statement > gross Profit
10202000
Quarters > 3 > income Statement > operating Expenses
20882000
Quarters > 3 > income Statement > operating Income
-10680000
Quarters > 3 > income Statement > interest Expense
1710768
Quarters > 3 > income Statement > pretax Income
6437000
Quarters > 3 > income Statement > net Income
5922000
Quarters > 3 > income Statement > eps
0.059164460545951696
Quarters > 3 > income Statement > dividends Per Share
0
Quarters > 3 > income Statement > shares Outstanding
100093873
Quarters > 3 > income Statement > income Tax Expense
514000
Quarters > 3 > income Statement > EBITDA
14174000
Quarters > 3 > income Statement > operating Margin
-83.98207124321773
Quarters > 3 > income Statement > total Other Income Expense Net
17117000
Quarters > 3 > balance Sheet > cash
143251000
Quarters > 3 > balance Sheet > short Term Investments
117055000
Quarters > 3 > balance Sheet > receivables
23037000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
287069000
Quarters > 3 > balance Sheet > property Plant Equipment
75863000
Quarters > 3 > balance Sheet > total Assets
383544000
Quarters > 3 > balance Sheet > payables
18664000
Quarters > 3 > balance Sheet > short Term Debt
13226000
Quarters > 3 > balance Sheet > long Term Debt
43990000
Quarters > 3 > balance Sheet > total Liabilities
252511000
Quarters > 3 > balance Sheet > equity
131033000
Quarters > 3 > cash Flow > net Income
5922000
Quarters > 3 > cash Flow > depreciation
5829000
Quarters > 3 > cash Flow > change In Working Capital
5262000
Quarters > 3 > cash Flow > cash From Operations
-47000
Quarters > 3 > cash Flow > capital Expenditures
1745000
Quarters > 3 > cash Flow > cash From Investing
-16661000
Quarters > 3 > cash Flow > cash From Financing
2925000
Quarters > 3 > cash Flow > net Change In Cash
-15836000
Quarters > 3 > ratios > PE
0.059164460545951696
Quarters > 3 > ratios > PB
3.5749721493059
Quarters > 3 > ratios > ROE
4.5194721940274585
Quarters > 3 > ratios > ROA
1.5440210249671484
Quarters > 3 > ratios > FCF
-1792000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-0.1409137375167099
Quarters > 3 > health Score
39
Valuation > metrics > PE
0.0058709195115873416
Valuation > metrics > PB
4.672873663886621
Valuation > final Score
53.27126336113379
Valuation > verdict
22.1% Undervalued
Profitability > metrics > ROE
0.586197973685782
Profitability > metrics > ROA
0.2662832910625562
Profitability > metrics > Net Margin
0.0167462754463778
Profitability > final Score
4
Profitability > verdict
Weak
Risk > metrics > Debt Equity
2.4141304564183206
Risk > metrics > Interest Coverage
3.816326530612245
Risk > final Score
33
Risk > verdict
High
Liquidity > metrics > Current Ratio
9.055638176994856
Liquidity > metrics > Quick Ratio
9.055638176994856
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
31.651100287300107
Prev Valuations > 1
39.66294653196104
Prev Valuations > 2
64.250278506941
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
45
Prev Risks > 0
0
Prev Risks > 1
-12
Prev Risks > 2
5
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:20:32.827Z
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACellectis’ Allogeneic CAR-T Potential Still Justifies A “Buy” (NASDAQ:CLLS) - Seeking Alpha
12/12/2025
Cellectis’ Allogeneic CAR-T Potential Still Justifies A “Buy” (NASDAQ:CLLS) Seeking Alpha
Read more →Pullback Watch: Should I hold or sell CLLS stock in 2025 - Weekly Earnings Recap & Free AI Powered Buy and Sell Recommendations moha.gov.vn
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$7.2
Analyst Picks
Strong Buy
1
Buy
2
Hold
2
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 13.52% of the total shares of Cellectis SA
1.
Long Focus Capital Management, LLC(4.702%)
since
2025/06/30
2.
B Group, Inc(3.2459%)
since
2025/06/30
3.
UBS Asset Mgmt Americas Inc(3.1683%)
since
2025/06/30
4.
UBS Lux Dgtl Hlth Eq Fd seeding P acc(1.3004%)
since
2025/07/31
5.
Macquarie Group Ltd(0.2261%)
since
2025/06/30
6.
Macquarie Healthcare I(0.2261%)
since
2025/07/31
7.
Galileo - Biotech Innovation Fund S USD(0.2253%)
since
2025/02/28
8.
Morgan Stanley - Brokerage Accounts(0.0925%)
since
2025/06/30
9.
LPL Financial Corp(0.0854%)
since
2025/06/30
10.
BNP Paribas Arbitrage, SA(0.0412%)
since
2025/06/30
11.
Millennium Management LLC(0.0355%)
since
2025/06/30
12.
Susquehanna International Group, LLP(0.0343%)
since
2025/06/30
13.
Prisma Cube(0.0299%)
since
2025/03/31
14.
P & S Renditefonds T(0.0299%)
since
2025/06/30
15.
First Affirmative Financial Network(0.0258%)
since
2025/03/31
16.
UBS Group AG(0.0255%)
since
2025/06/30
17.
Wells Fargo & Co(0.0171%)
since
2025/06/30
18.
HARBOUR INVESTMENTS, INC.(0.0045%)
since
2025/06/30
19.
Rhumbline Advisers(0.0019%)
since
2025/06/30
20.
JPMorgan Chase & Co(0.0018%)
since
2025/06/30
21.
Hanson Mcclain Inc(0.0005%)
since
2025/06/30
22.
POM Investment Strategies, LLC(0.0005%)
since
2025/06/30
23.
Principal Securities Inc(0.0002%)
since
2025/06/30
24.
Advisor Group Holdings, Inc.(0.0001%)
since
2025/06/30
25.
Bank of America Corp(0.0001%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.